Inloggad som:
avslutad_Commands, ACE-536-MDS-002
Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
avslutad_Commands, ACE-536-MDS-002
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin alfa for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Risk Myelodyplastic Syndroms (MDS) in ESA Naive Subjects who require Red Blood Cell Transfusions.
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin alfa for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Risk Myelodyplastic Syndroms (MDS) in ESA Naive Subjects who require Red Blood Cell Transfusions.
PLACEHOLDER
Mer information om studien för vårdgivare
Behandling
Ej tillämpbar
Ej tillämpbar
Företag
Studien ändrades senast av: studysonia (2023-05-10)